We are live on ! Find out more
LRMR icon

Larimar Therapeutics

116 hedge funds and large institutions have $245M invested in Larimar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 32 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

432% more call options, than puts

Call options by funds: $2.13M | Put options by funds: $400K

38% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 32

1.4% less ownership

Funds ownership: 100.81%99.41% (-1.4%)

6% less funds holding

Funds holding: 123116 (-7)

19% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 27

42% less capital invested

Capital invested by funds: $421M → $245M (-$176M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
116
Holders Change
-7
Holders Change %
-5.69%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
22
Increased
44
Reduced
32
Closed
27
Calls
$2.13M
Puts
$400K
Net Calls
+$1.73M
Net Calls Change
-$243K
Name Holding Trade Value Shares
Change
Change in
Stake
N
26
Nuveen
North Carolina
$676K
Morgan Stanley
27
Morgan Stanley
New York
$659K +$138K +20,951 +14%
GCP
28
GSA Capital Partners
United Kingdom
$575K +$271K +41,125 +38%
Charles Schwab
29
Charles Schwab
California
$484K
TI
30
Trexquant Investment
Connecticut
$476K -$185K -28,041 -19%
Wellington Management Group
31
Wellington Management Group
Massachusetts
$449K +$71.4K +10,821 +10%
Marshall Wace
32
Marshall Wace
United Kingdom
$427K +$250K +37,810 +52%
JF
33
Jump Financial
Illinois
$416K +$85.1K +12,893 +14%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$389K +$12K +1,823 +2%
Two Sigma Investments
35
Two Sigma Investments
New York
$332K -$223K -33,719 -28%
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$314K -$170K -25,753 -24%
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
$308K +$525K +79,496 New
Barclays
38
Barclays
United Kingdom
$273K +$68.6K +10,393 +17%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$262K +$308K +46,722 +224%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$259K -$199K -30,100 -31%
XT
41
XTX Topco
Cayman Islands
$247K +$320K +48,481 +316%
IC
42
Ikarian Capital
Texas
$226K -$13 -2 -0%
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$224K +$121K +18,373 +46%
American Century Companies
44
American Century Companies
Missouri
$218K +$91.7K +13,891 +33%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$217K +$3.43K +519 +0.9%
EC
46
EntryPoint Capital
New York
$210K +$238K +36,045 +198%
Bank of America
47
Bank of America
North Carolina
$206K +$26.3K +3,980 +8%
UBS Group
48
UBS Group
Switzerland
$206K +$220K +33,257 +167%
AA
49
ALPS Advisors
Colorado
$200K +$341K +51,590 New
MCM
50
Monimus Capital Management
New Jersey
$182K +$311K +47,100 New

LRMR Hedge Fund Activity: Q4 2024 in Review

116 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2024, worth a combined $245M — down 42% from $421M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of LRMR and 22 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 44 added.

The largest buyer was Janus Henderson Group, adding an estimated $5.79M. The largest seller was Woodline Partners, cutting an estimated $4.11M.

  • 116 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2024, down from 123 in Q3 2024.
  • Funds reported $245M of Larimar Therapeutics stock for Q4 2024, down 42% quarter-over-quarter.
  • 22 funds opened new Larimar Therapeutics positions in Q4 2024 and 27 closed out, a net change of -5 holders.
  • The largest Larimar Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $5.79M added.
  • The largest Larimar Therapeutics seller in Q4 2024 was Woodline Partners, an estimated $4.11M sold.

Based on aggregated 13F filings for Q4 2024.